BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 11762559)

  • 1. Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection.
    Zhao Q; Zhou H; Pesco-Koplowitz L
    J Clin Pharmacol; 2001 Dec; 41(12):1319-28. PubMed ID: 11762559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection.
    Zhou H; Goldman M; Wu J; Woestenborghs R; Hassell AE; Lee P; Baruch A; Pesco-Koplowitz L; Borum J; Wheat LJ
    J Clin Pharmacol; 1998 Jul; 38(7):593-602. PubMed ID: 9702843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy.
    Boogaerts MA; Maertens J; Van Der Geest R; Bosly A; Michaux JM; Van Hoof A; Cleeren M; Wostenborghs R; De Beule K
    Antimicrob Agents Chemother; 2001 Mar; 45(3):981-5. PubMed ID: 11181397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units.
    Vandewoude K; Vogelaers D; Decruyenaere J; Jaqmin P; De Beule K; Van Peer A; Woestenborghs R; Groen K; Colardyn F
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2714-8. PubMed ID: 9420044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers.
    Barone JA; Moskovitz BL; Guarnieri J; Hassell AE; Colaizzi JL; Bierman RH; Jessen L
    Pharmacotherapy; 1998; 18(2):295-301. PubMed ID: 9545149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
    Abdel-Rahman SM; Jacobs RF; Massarella J; Kauffman RE; Bradley JS; Kimko HC; Kearns GL; Shalayda K; Curtin C; Maldonado SD; Blumer JL
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2668-73. PubMed ID: 17517842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers.
    Gubbins PO; McConnell SA; Gurley BJ; Fincher TK; Franks AM; Williams DK; Penzak SR; Saccente M
    Pharmacotherapy; 2004 Apr; 24(4):460-7. PubMed ID: 15098799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis.
    Conway SP; Etherington C; Peckham DG; Brownlee KG; Whitehead A; Cunliffe H
    J Antimicrob Chemother; 2004 May; 53(5):841-7. PubMed ID: 15044430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linking the concentrations of itraconazole and 2-hydroxypropyl-β-cyclodextrin in human intestinal fluids after oral intake of Sporanox
    Berben P; Stappaerts J; Vink MJA; Domínguez-Vega E; Somsen GW; Brouwers J; Augustijns P
    Eur J Pharm Biopharm; 2018 Nov; 132():231-236. PubMed ID: 29959034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients.
    Mohr JF; Finkel KW; Rex JH; Rodriguez JR; Leitz GJ; Ostrosky-Zeichner L
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3151-3. PubMed ID: 15273137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules.
    Glasmacher A; Hahn C; Molitor E; Marklein G; Sauerbruch T; Schmidt-Wolf IG
    Mycoses; 1999; 42(11-12):591-600. PubMed ID: 10680434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.
    Groll AH; Wood L; Roden M; Mickiene D; Chiou CC; Townley E; Dad L; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2554-63. PubMed ID: 12121932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis.
    Reynes J; Bazin C; Ajana F; Datry A; Le Moing JP; Chwetzoff E; Levron JC
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2554-8. PubMed ID: 9371367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations.
    Buchanan CM; Buchanan NL; Edgar KJ; Klein S; Little JL; Ramsey MG; Ruble KM; Wacher VJ; Wempe MF
    J Pharm Sci; 2007 Nov; 96(11):3100-16. PubMed ID: 17712849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis.
    Caillot D
    Acta Haematol; 2003; 109(3):111-8. PubMed ID: 12714819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.
    Caillot D; Bassaris H; McGeer A; Arthur C; Prentice HG; Seifert W; De Beule K
    Clin Infect Dis; 2001 Oct; 33(8):e83-90. PubMed ID: 11550120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children.
    de Repentigny L; Ratelle J; Leclerc JM; Cornu G; Sokal EM; Jacqmin P; De Beule K
    Antimicrob Agents Chemother; 1998 Feb; 42(2):404-8. PubMed ID: 9527794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats.
    Boothe DM; Herring I; Calvin J; Way N; Dvorak J
    Am J Vet Res; 1997 Aug; 58(8):872-7. PubMed ID: 9256973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of itraconazole/2-hydroxypropyl-beta-cyclodextrin inclusion complex in aqueous propylene glycol solution.
    Miyake K; Irie T; Arima H; Hirayama F; Uekama K; Hirano M; Okamaoto Y
    Int J Pharm; 1999 Mar; 179(2):237-45. PubMed ID: 10053216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.
    Barone JA; Moskovitz BL; Guarnieri J; Hassell AE; Colaizzi JL; Bierman RH; Jessen L
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1862-5. PubMed ID: 9661037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.